Merkel Cell Carcinoma Treatment Summary
Therapeutic options have been historically limited for patients with advanced disease.
This PDQ® summary provides up‑to‑date information on the evidence‑based treatment of Merkel cell carcinoma (MCC), a rare but aggressive cutaneous neuroendocrine carcinoma. It details the epidemiology, diagnostic work‑up, staging, and therapeutic options for localized, regional, and metastatic disease, including surgery, radiation, and emerging immunotherapeutic strategies.
Patients with advanced Merkel cell carcinoma often experience rapid disease progression and high mortality; limited effective therapies have historically led to poor durable responses, underscoring the need for improved treatment approaches.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice
- Milestones in Chronic Lymphocytic Leukemia
- Trial Results Show Majority of Patients With CLL Achieve uMRD With VenO
- On the architecture of translational research designed to control chronic lymphocytic leukemia
- Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)